Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland E Kontermann

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2009
Strategies to extend plasma half-lives of recombinant antibodiesRoland E Kontermann
Current Opinion in Biotechnology|August 25, 2011
Strategies for extended serum half-life of protein therapeuticsRoland E Kontermann
Archives of Biochemistry and Biophysics|March 27, 2012
Antibody-cytokine fusion proteinsRoland E Kontermann
Mabs|March 29, 2012
Dual targeting strategies with bispecific antibodiesRoland E Kontermann
Expert Opinion on Biological Therapy|March 12, 2016
Half-life extended biotherapeuticsRoland E Kontermann
Current Opinion in Molecular Therapeutics|April 8, 2010
Alternative antibody formatsRoland E Kontermann
Methods (San Diego, Calif.)|August 18, 2004
Intrabodies as therapeutic agentsRoland E Kontermann
Acta Pharmacologica Sinica|January 22, 2005
Recombinant bispecific antibodies for cancer therapyRoland E Kontermann
Current Opinion in Molecular Therapeutics|March 2, 2006
Immunoliposomes for cancer therapyRoland E Kontermann
Current Opinion in Molecular Therapeutics|August 19, 2007
Recombinant bispecific antibodies for cellular cancer immunotherapyDafne Müller, Roland E Kontermann
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2009
Strategies to extend plasma half-lives of recombinant antibodiesRoland E Kontermann
Current Opinion in Biotechnology|August 25, 2011
Strategies for extended serum half-life of protein therapeuticsRoland E Kontermann
Archives of Biochemistry and Biophysics|March 27, 2012
Antibody-cytokine fusion proteinsRoland E Kontermann
Mabs|March 29, 2012
Dual targeting strategies with bispecific antibodiesRoland E Kontermann
Expert Opinion on Biological Therapy|March 12, 2016
Half-life extended biotherapeuticsRoland E Kontermann
Current Opinion in Molecular Therapeutics|April 8, 2010
Alternative antibody formatsRoland E Kontermann
Methods (San Diego, Calif.)|August 18, 2004
Intrabodies as therapeutic agentsRoland E Kontermann
Acta Pharmacologica Sinica|January 22, 2005
Recombinant bispecific antibodies for cancer therapyRoland E Kontermann
Current Opinion in Molecular Therapeutics|March 2, 2006
Immunoliposomes for cancer therapyRoland E Kontermann
Current Opinion in Molecular Therapeutics|August 19, 2007
Recombinant bispecific antibodies for cellular cancer immunotherapyDafne Müller, Roland E Kontermann
Pageof 15